Since 2006, Elixir has advised over 50 boards, shareholders and management teams across the biopharma ecosystem from large multinationals and small pre-revenue startups:
Elixir's core activities centre on the provision of interim and project-based corporate development/advisory services to companies across the healthcare services, biopharmaceutical and med tech industries.
Elixir has worked on a number of M&A transactions including spin-outs and roll-ups in the public sector and private CRO and healthcare distribution space where it provided strategic support, origination and execution services. Elixir has also implemented knowledge graphs to enhance the outcomes in a number of these processes.
Elixir has worked both on behalf of company management and/or their PE owners and the NHS, to review strategic options and to deliver strategic plans. Elixir has provided services in health tech; clinical research services, medtech and biotech companies.
Elixir has advised accross a wide variety of strategic and shared risk partnerships structures including those commonly employed by biotech companies and CROs. Elixir has worked on strategic deals as diverse as negotiating access to patient records with the NHS to the £500m five-year clinical development agreement between Quintiles and Merck KGaA.
Elixir can call upon its graph databases to undertake sophisticated landscaping and valuation exercises which add granularity and proprietary insights to any deal process.